Arovella Therapeutics Ltd has released a press release.
Reinstatement to Official Quotation
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Prospectus
- Arovella $15m Placement to fund Phase 1
- Voluntary Suspension
- Trading Halt
- Arovella $20m Placement - fully funded to complete Phase 1
Later from Arovella Therapeutics
- Research Agreement with University of North Carolina
- S&P DJI Announces March 2025 Quarterly Rebalance
- Appendix 4E and Annual Report
- S&P DJI Announces September 2025 Quarterly Rebalance
- Arovella receives R&D tax rebate of $3.21 million
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics